OncoGenex prices $50 million offering

OncoGenex Pharmaceuticals (NASDAQ: OGXI) has priced a public offering of 3,174,602 units at $15.75 (U.S.) per unit, with each unit consisting of one common share and one-half of a warrant. The stock closed at 18.75 on Monday. Net proceeds of about $46.7 million will be used primarily to advance the company’s product pipeline, including its [...]

Bioniche shares jump 34% on Endo taking up global rights

Shares of Bioniche Life Sciences touched a 52-week high on the Toronto Stock Exchange Friday after marketing partner Endo Pharmaceuticals elected to exercise its option for exclusive global rights to develop and market Bioniche’s non-muscle-invasive bladder cancer product. As a result, Endo (NASDAQ:ENDP) will all assume all external development expenses for the product, Bioniche (TSX:BNC) [...]